Antibodies Industry Data Book | Forecast 2030
Antibodies Industry Data Book - Antibodies Production, Research Antibody, Monoclonal & Cancer Monoclonal Antibody, Mammalian IgG Polyclonal Antibody Market Size, Share, Trends Analysis, And Segment Forecasts, 2022 – 2030
Grand View Research’s Antibodies Industry data book is a collection of market sizing & forecast insights, market dynamics & trends, opportunity assessment, regulatory & technology framework, pricing intelligence, competitive benchmarking analyses, and macro-environmental analysis studies. Within the purview of the databook, such information is systematically analyzed and provided in the form of summary presentations and detailed outlook reports on individual areas of research.
Access the Global Antibodies Industry Data Book, 2022 to 2030, compiled with details like market sizing & forecast insights, market dynamics & trends, opportunity assessment, regulatory & technology framework, pricing intelligence, competitive benchmarking analyses, and macro-environmental analysis studies.
Monoclonal Antibodies Market Report Highlights
The global monoclonal antibodies market is projected to reach USD 494.53 billion by 2030, at a compound annual growth rate (CAGR) of 11.04% in the forecast period, according to a new report by Grand View Research, Inc.
- By source type, the human mAbs segment held the largest share of 54.3% in 2022 due to the low immunogenicity offered and increasing cancer treatment applications of these antibodies
- In vitro production type held a dominating share of 76.9% in 2022 due to the low contamination levels offered by the technique and the availability of advanced bio-manufacturing capabilities
- The oncology segment dominated the market in 2022 due to the rising number of approvals for mAb cancer therapeutics and increasing scientific and patient awareness about such therapies
- Hospitals accounted for the largest share of the end-use segment in 2022 due to the widespread use of mAbs for cancer treatment in hospitals and increasing healthcare expenditure favoring the adoption of such therapeutics
- North America accounted for 46.1% of the market value in 2022 due to the availability of advanced healthcare infrastructure, high growth in cancer incidence, and local presence of key players such as Pfizer Inc., Amgen, Inc., and Merck & Co., among others
Antibody Production Market Report Highlights
The global antibody production market size is expected to reach a value of USD 22.6 billion by 2025, at a CAGR of 13.5% according to a new report by Grand View Research, Inc.
- Downstream processing was the largest revenue-grossing segment of the antibody production market in 2016. It is also expected to exhibit the highest CAGR during the forecast period, owing to the large application of chromatography devices and resins in downstream processing
- The monoclonal antibody segment was leading in 2016, due to its higher demand in treatment of chronic diseases including cancer, blood disorders, and growth hormone deficiency
- The pharmaceutical and biotechnology companies segment dominated the overall market in terms of revenue in 2016, owing to the large production of therapeutic antibodies and high investment in R&D by companies for drug development
- North America was the largest revenue-generating region of the market in the year 2016. This region is expected to maintain its position during the forecast period because of the presence of several leading biopharmaceuticals and biotechnology companies in this region
Cancer Monoclonal Antibodies Market Report Highlights
The global cancer monoclonal antibodies market size is expected to reach USD 281.78 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 18.20% from 2023 to 2030.
- By type, the humanized segment held a larger share of the market in 2021 owing to factors such as, low cost, availability, and quick production time for mouse monoclonal antibodies. However, the human segment is expected to hold the highest CAGR during the forecast period due to an increase in the number of product approvals and product launches
- The blood cancer application segment held a significant revenue share in 2021 owing to an increase in the prevalence of hematological disorders along with a robust pipeline. In addition, the lung cancer segment is poised to expand at the highest CAGR during the forecast period
- In 2021, the hospital segment was the leading end-user segment due to an upsurge in the number of patient hospitalizations. In addition, the availability of innovative drug therapies in the facility drives the patient preference
Order your copy of the Free Sample of “Antibodies Industry Data Book - Antibodies Production, Research Antibody, Monoclonal & Cancer Monoclonal Antibody, Mammalian IgG Polyclonal Antibody Market Size, Share, Trends Analysis, And Segment Forecasts, 2022 – 2030” Data Book, published by Grand View Research
Research Antibodies Market Report Highlights
The global research antibodies market size is expected to reach USD 2.21 billion by 2030, expanding at a CAGR of 4.76% from 2023 to 2030, according to a new report by Grand View Research, Inc.
- In 2022, the primary product segment held the largest revenue share due to the higher specificity and direct detection capabilities offered by the antibodies
- By type, monoclonal antibodies captured a substantial share in 2022 due to the increase in COVID-19-related research activities involving the use of such antibodies
- The western blotting technology segment held a dominant share of over 29.57% in 2022 because of the increasing investments in R&D activities by several biotechnology and pharmaceutical companies and the rapidly growing applications of antibodies in western blots created for proteomic studies
- By end-use, academic and research institutions held the largest share of over 61.17% in 2022 due to a rise in funding opportunities and growth in the number of scientific institutions involved in life sciences
Mammalian Polyclonal IgG Antibody Market Report Highlights
The global mammalian polyclonal IgG antibody market size is expected to reach USD 1.67 billion by 2030, registering a CAGR of 5.01% of the overall revenue, according to a new report by Grand View Research, Inc.
- Based ontypes, the mouse segment is expected to register the fastest CAGR during the forecast period. The growth is attributed to the similar characteristic of its immune system as humans, resulting in low variation of the outcome during the trials
- Basedon products, the metabolic biomarkers segment captured the largest share in 2022 due to the high incidence of chronic diseases
- The ELISA applicationsegment is estimated to hold the largest share by2030. As it offers more accurate diagnoses of diseases, such as AIDS, Lyme disease, Rocky Mountain spotted fever, chickenpox, squamous cell carcinoma, syphilis, shingles, and other infections, than other antibody-based assays.
- The pharma & biotech companies end-user segment held the highest share in 2022and is likely to remain dominant over the forecast period
- Companies are focusing on the adoption of smarter, novel, and advanced approaches for the development of new diagnostic tests & drugs
Go through the table of content of Antibodies Industry Data Book to get a better understanding of the Coverage & Scope of the study
Competitive Landscape
Key players operating in the Antibodies industry are –
- DANAHER CORPORATION
- SARTORIUS AG
- THERMO FISHER SCIENTIFIC, INC.
- GE HEALTHCARE
- MERCK KGAA
- EPPENDORF AG
- CELLAB GMBH
- INTEGRA BIOSCIENCES AG
- NOVARTIS AG
- PFIZER INC.
- AMGEN INC.
- GLAXOSMITHKLINE PLC
- DAIICHI SANKYO COMPANY, LIMITED
Grand View Research’s Antibodies Industry data book is a collection of market sizing information & forecasts, regulatory data, reimbursement structure, competitive benchmarking analyses, macro-environmental analyses, and regulatory & technological framework studies. Within the purview of the database, all such information is systematically analyzed and provided in the form of presentations and detailed outlook reports on individual areas of research.
Check out more Industry Data Books, published by Grand View Research
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
It includes the size, share, growth, trends, key players, segments and regional analysis in detail during the study year 2020-2027.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the monoclonal antibodies market include Roche, Eli Lilly, Genentech, Pfizer, Biogen Idec.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Monoclonal Antibodies Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/monoclonal-antibodies-market/download-sampleMarket DynamicsProduction of monoclonal antibodies is an old practice in laboratory research.
The continued interest in antibody product development is driven by the rapid advancement and understanding of disease at a molecular level.
MAbs are increasingly used for applications such as research and diagnosis, therapeutic tools in cancer and immunological disorders, and pharmacy, thus generating a great demand in the industry.
Currently, MAbs account for one-third of all the new treatments for leukaemia, arthritis, breast cancer, and transplant, their role in disease prediction and detection offers promise.
